Chemours: Neutral Stance Maintained as Temporary HFC Tailwinds Offset Cautious Outlook; $18 Price Target Unchanged

Analyst Duffy Fischer from Goldman Sachs maintained a Hold rating on Chemours Company and keeping the price target at $18.00.

Duffy Fischer has given his Hold rating due to a combination of factors, including Chemours’ stronger‑than‑expected first‑quarter performance and a more cautious outlook for the coming quarters. The company materially exceeded consensus EBITDA in Q1, driven largely by outsized gains in Thermal & Specialized Solutions from elevated Freon pricing and ongoing demand for Opteon, while other segments such as Advanced Performance Materials are still normalizing after prior operational disruptions.

However, management’s second‑quarter EBITDA guidance sits notably below market expectations, and a meaningful portion of current earnings strength appears tied to temporary HFC pricing benefits that may not be sustainable. With the stock already up sharply year‑to‑date, expectations around TiO2 need to be reset lower, and the risk/reward looks balanced at this stage, supporting a Neutral stance and an unchanged $18 price target.

In another report released yesterday, Morgan Stanley also reiterated a Hold rating on the stock with a $17.00 price target.